


# RESEARCH REPORT



## Cell Based Assay & High Content Screening Markets

Forecasts by User and Product. With Executive and  
Consultant Guides. including Customized Forecasting and  
Analysis. 2023 to 2027



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

## Table of Contents

1	Market Guides.....	17
1.1	Situation Analysis.....	18
1.2	Guide for Executives and Marketing Staff .....	20
1.3	Guide for Investment Analysts and Management Consultants.....	21
2	Introduction and Market Definition .....	22
2.1	What are Cell Based Assays?.....	23
2.2	Clinical Trial Failures .....	26
2.2.1	Immuno-oncology Plays a Leading Role in Cell Based Assays ...	28
2.3	Infectious Disease Will Play a Larger Role .....	30
2.4	Market Definition .....	30
2.4.1	Market Size .....	30
2.4.2	Currency.....	31
2.4.3	Years.....	31
2.5	Methodology .....	32
2.5.1	Methodology .....	32
2.5.2	Sources .....	32
2.5.3	Authors.....	33
2.6	U.S. Medical Market and Pharmaceutical Research Spending - Perspective.....	34

1.5.1 U.S. Expenditures for Pharmaceutical Research .....	34
3 Cell Based Assays – Guide to Technology .....	35
3.1 Cell Cultures .....	36
3.1.1 Cell Lines .....	36
3.1.2 Primary Cells .....	45
3.1.3 Stem Cells .....	46
3.1.4 iPSC's – The Special Case .....	47
3.2 Cell Assays .....	48
3.3 Cell Viability Assays .....	50
3.4 Cell Proliferation Assays .....	52
3.5 Cytotoxicity Assays .....	53
3.6 Cell Senescence Assays .....	53
3.7 Apoptosis .....	54
3.8 Autophagy .....	54
3.9 Necrosis .....	55
3.10 Oxidative Stress .....	56
3.11 2D vs. 3D .....	58
3.12 Signalling Pathways, GPCR .....	60
3.13 Immune Regulation & Inhibition .....	62
3.14 Reporter Gene Technology .....	63
3.15 CBA Design & Development .....	63
3.16 Cell Based Assays – The Takeaway .....	65
4 Industry Overview .....	66

4.1	Players in a Dynamic Market .....	67
4.1.1	Academic Research Lab .....	68
4.1.2	Contract Research Organization .....	68
4.1.3	Genomic Instrumentation Supplier .....	69
4.1.4	Cell Separation and Viewing Supplier .....	69
4.1.5	Cell Line and Reagent Supplier .....	70
4.1.6	Pharmaceutical Company .....	70
4.1.7	Audit Body .....	70
4.1.8	Certification Body .....	70
5	Market Trends .....	72
5.1	Factors Driving Growth .....	73
5.1.1	Candidate Growth .....	74
5.1.2	Immuno-oncology .....	74
5.1.3	Genomic Blizzard .....	76
5.1.4	Technology Convergence .....	76
5.1.5	The Insurance Effect .....	76
5.2	Factors Limiting Growth .....	78
5.2.1	CBA Development Challenges .....	78
5.2.2	Instrument Integration .....	79
5.2.3	Protocols .....	79
5.3	Technology Development .....	80
5.3.1	3D Assays .....	80
5.3.2	Automation .....	80

5.3.3	Software.....	81
5.3.4	Primary Cells.....	81
5.3.5	Signalling and Reporter Genes .....	82
5.3.6	The Next Five Years.....	83
6	Cell Based Assays Recent Developments.....	84
6.1	Recent Developments – Importance and How to Use This Section 85	
6.1.1	Importance of These Developments.....	85
6.1.2	How to Use This Section .....	85
6.2	Charles River Laboratories Acquires SAMDI Tech .....	85
6.3	Axion BioSystems Launches New High-Throughput Live-Cell Imaging Platform.....	87
6.4	Fujifilm’s Life Sciences Invests in PhenoVista Biosciences.....	88
6.5	Nucleai Launches New Multiplex Imaging Spatial Analysis Solution 89	
6.6	BIO-TECHNE ANNOUNCES MULTI-OMIC RNASCOPE ASSAYS .....	90
6.7	Indivumed, CellPhenomics Partner on Cancer Drug Target Research.....	91
6.8	Synthego to Accelerate Drug Discovery .....	92
6.9	Long COVID Detected By Cell-Based Assay .....	94
6.10	Nanolive closes a USD 20 million Funding Round.....	97
6.11	Depixus Seeks to Commercialize 'Magnetic Tweezers' for Drug Discovery .....	98
6.12	BioAuxilium Research Expands its Cell Signaling Assay Portfolio..	102
6.13	Droplet Genomics Debuts New Microfluidic Screening Platform	103

6.14	DLP Plus Single-Cell Sequencing Method Spreads From Canada to Cancer Labs Worldwide .....	108
6.15	Secondcell Bio to Make Creation of Cell Lines Easy .....	113
6.16	Nanolitre-scale cell assays developed with droplet microarray-mass spec .....	119
6.17	Thermo Fisher Scientific Acquires Cell Sorting Technology .....	121
6.18	Cellink to Distribute Phasefocus High-Content Cell Imaging Platform.....	122
6.19	Axxam and FUJIFILM Cellular Dynamics Announce Strategic Alliance .....	123
6.20	Cancer Genetics to Acquire Organoid Startup Stemonix.....	124
6.21	Curi Bio Acquires Artificial Intelligence Firm Dana Solutions .....	126
6.22	CRISPR Screens Uncover Novel Cancer Therapy Targets .....	127
6.23	ERS Genomics Licenses CRISPR-Cas9 Patents to Axxam .....	132
6.24	New Transcriptomics Assay Facilitates Compound Screens .....	133
6.25	Carta Biosciences Betting on Gene Interaction Mapping .....	136
6.26	High-throughput Identifies cancer drug candidates .....	140
6.27	Velabs Therapeutics partners with Alytas Therapeutics to develop a novel immune-based therapy for obesity .....	141
6.28	InSphero platform selected to test Cycleron's sGC stimulator technology .....	142
6.29	Ocello to provide in vitro research services to Merus.....	144
6.30	Charles River Laboratories to acquire Citoxlab .....	145
6.31	Reaction Biology Corporation Purchases ProQinase GmbH.....	147
7	Profiles of Key Cell Based Assay Companies .....	149



7.1	Abcam.....	150
7.2	Agilent/Dako.....	152
7.3	Aurora Biomed.....	156
7.4	Axxam.....	158
7.5	Beckman Coulter Diagnostics.....	160
7.6	Becton, Dickinson and Company.....	162
7.7	Berkley Lights.....	165
7.8	BioIVT.....	166
7.9	Bio-Rad Laboratories, Inc.....	168
7.10	BioTek Instruments.....	171
7.11	BioVision, Inc.....	173
7.12	BMG Labtech.....	175
7.13	Cell Biolabs, Inc.....	176
7.14	Cell Signaling Technology, Inc.....	177
7.15	Charles River Laboratories.....	179
7.16	Cisbio Bioassays.....	181
7.17	Corning, Inc.....	183
7.18	Cyttek Biosciences.....	185
7.19	Cytovale.....	188
7.20	Enzo Biochem.....	189
7.21	Eurofins DiscoverX Corporation.....	191
7.22	Evotec AG.....	193
7.23	Excellerate Bioscience.....	195

7.24	Fujifilm Cellular Dynamics International .....	196
7.25	Genedata .....	198
7.26	Hemogenix .....	200
7.27	Invivogen .....	202
7.28	Leica Biosystems .....	204
7.29	Lonza Group Ltd. ....	206
7.30	Luminex Corp (DiaSorin) .....	208
7.31	Merck & Co., Inc.....	210
7.32	Miltenyi Biotec.....	212
7.33	Molecular Devices.....	214
7.34	Nanon.....	216
7.35	Ncardia .....	218
7.36	New England Biolabs, Inc.....	220
7.37	Novogene Bioinformatics Technology Co., Ltd. ....	222
7.38	Olympus.....	225
7.39	Origene Technologies.....	227
7.40	Perkin Elmer .....	228
7.41	Promega.....	230
7.42	Qiagen.....	232
7.43	Reaction Biology.....	235
7.44	Recursion Pharma .....	236
7.45	Roche Diagnostics.....	238
7.46	Sartorius.....	243

7.47 Sartorius-ForteBio.....	245
7.48 Sartorius-IntelliCyt.....	246
7.49 Singleron Biotechnologies .....	247
7.50 Sony Biotechnology .....	248
7.51 SPT Labtech.....	250
7.52 Stemcells Technologies Canada Inc.....	252
7.53 Tecan .....	254
7.54 Thermo Fisher Scientific Inc. ....	256
7.55 Vitro Biopharma.....	260
8 Global Market Size.....	262
8.1 Global Market Overview by Country.....	263
8.1.1 Table – Global Market by Country.....	263
8.1.2 Chart - Global Market by Country .....	264
8.2 Global Market by User - Overview .....	265
8.2.1 Table – Global Market by User.....	265
8.2.2 Chart – Global Market by User – Base/End Year Comparison..	266
8.2.3 Chart – Global Market by User – Base Year .....	267
8.2.4 Chart – Global Market by User – End Year.....	268
8.2.5 Chart – Global Market by User – Share by Year.....	269
8.3 Global Market by Product Class - Overview .....	270
8.3.1 Table – Global Market by Product Class.....	270
8.3.2 Chart – Global Market by Product Class – Base/End Year Comparison .....	271

8.3.3	Chart – Global Market by Product Class – Base Year .....	272
8.3.4	Chart – Global Market by Product Class – End Year.....	273
8.3.5	Chart – Global Market by Product Class – Share by Year .....	274
9	Global Market by User Type .....	275
9.1	Pharma .....	276
9.1.1	Table Pharma – by Country .....	276
9.1.2	Chart - Pharma Growth.....	277
9.2	Research.....	278
9.2.1	Table Research – by Country.....	278
9.2.2	Chart - Research Growth .....	279
9.3	Industry/Cosmetic .....	280
9.3.1	Table Industry/Cosmetic – by Country .....	280
9.3.2	Chart - Industry/Cosmetic Growth.....	281
10	Cell Based Assay by Product Class .....	282
10.1	Instrument .....	283
10.1.1	Table Instrument – by Country.....	283
10.1.2	Chart - Instrument Growth .....	284
10.2	Reagent.....	285
10.2.1	Table Reagent – by Country.....	285
10.2.2	Chart - Reagent Growth .....	286
10.3	Services.....	287
10.3.1	Table Services – by Country.....	287
10.3.2	Chart - Services Growth .....	288

10.4	Software.....	289
10.4.1	Table Software – by Country .....	289
10.4.2	Chart - Software Growth .....	290
11	Appendices.....	291
11.1	FDA Cancer Drug Approvals by Year.....	292
11.2	Clinical Trials Started.....	293
11.3	Share of Pharma R&D by Country.....	294

## Table of Tables

Table 1 The Large Variety of Cell Lines.....	38
Table 2 Some Common Viability Assays .....	51
Table 3 Oxidative Stress Related Diseases.....	57
Table 4 Important Signalling Pathways .....	60
Table 5 Market Players by Type.....	67
Table 6 Five Factors Driving Growth .....	73
Table 7 Three Factors Limiting Growth .....	78
Table 8 - Global Market by Region.....	263
Table 9 Global Market by User .....	265
Table 10 Global Market by Product Class .....	270
Table 11 Pharma by Country.....	276
Table 12 Research by Country .....	278
Table 13 Industry/Cosmetic by Country.....	280
Table 14 Instrument by Country .....	283
Table 15 Reagent by Country .....	285
Table 16 Services by Country .....	287
Table 17 Software by Country .....	289

## Table of Figures

Figure 1 Reasons for clinical Failure by Phase .....	26
Figure 2 Immunotherapy Clinical Trial Growth .....	29
Figure 3 Pharmaceutical Research Expenditures (\$Billion) .....	34
Figure 4 Oxidative Stress and Free Radical Toxicity.....	57
Figure 5 FDA Cancer Drug Approvals .....	74
Figure 6 The Changing Approach to Cancer Diagnostics.....	75
Figure 7 Growth rates of Cell Based Assays by Product Class .....	83
Figure 8 Global Market Share Chart.....	264
Figure 9 Global Market by User – Base vs. End Year .....	266
Figure 10 Global Market by User Base Year .....	267
Figure 11 Global Market by User End Year .....	268
Figure 12 User Share by Year .....	269
Figure 13 Global Market by Product Class – Base vs. End Year.....	271
Figure 14 Global Market by Product Class Base Year.....	272
Figure 15 Global Market by Product Class End Year .....	273
Figure 16 Product Class Share by Year.....	274
Figure 17 Pharma Growth .....	277
Figure 18 Research Growth .....	279
Figure 19 Industry/Cosmetic Growth .....	281
Figure 20 Instrument Growth.....	284

Figure 21 Reagent Growth.....286

Figure 22 Services Growth.....288

Figure 23 Software Growth .....290

Figure 24 FDA Cancer Drug Approvals by Year .....292

Figure 25 Clinical Trials for Immunotherapy by Year.....293

Figure 26 Share of Pharma R&D by Country .....294